Payment overview · 2025
General Payments
$79,465.15
264 reported records · 19 companies
Healthcare provider profile · identity verified
Kevin Patrick Mays, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · LEAWOOD, KS · NPI 1598735144
Verified facts
What the public records show
CMS Open Payments records show Kevin Patrick Mays, MD received $79,465.15 in general payments during 2025 across 264 reported records.
Supernus Pharmaceuticals, Inc. accounted for 33.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Azstarys, Caplyta, Ingrezza, Jornay Pm, Loreev Xr, Lybalvi, Nuplazid, Qelbree, Rexulti, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuplazid by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Lybalvi by this doctor in 2024.
Almatica Pharma LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOREEV XR as an associated drug or biological on 9621 records involving 4446 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Loreev Xr by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Jornay PM as an associated drug or biological on 46719 records involving 16334 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jornay Pm by this doctor in 2024.
Corium, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Azstarys as an associated drug or biological on 54930 records involving 15827 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Azstarys by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Invega Sustenna by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Supernus Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Qelbree as an associated drug or biological on 61278 records involving 18421 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qelbree by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trintellix by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26,568.43 | 33.4% | 50 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24,135.15 | 30.4% | 31 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21,960.38 | 27.6% | 46 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $4,907.31 | 6.2% | 31 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $424.86 | 0.5% | 17 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $400.42 | 0.5% | 23 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $196.10 | 0.2% | 16 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $167.51 | 0.2% | 7 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $154.25 | 0.2% | 15 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $98.53 | 0.1% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $84.88 | 0.1% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $83.84 | 0.1% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.60 | 0.1% | 4 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $46.89 | 0.1% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $40.73 | 0.1% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $40.31 | 0.1% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $34.02 | 0.0% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $30.73 | 0.0% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $20.21 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,255.00 | 16 |
| Honoraria | $22,800.00 | 9 |
| Consulting Fee | $10,407.50 | 2 |
| Travel and Lodging | $5,227.96 | 30 |
| Food and Beverage | $4,771.09 | 206 |
| Education | $3.60 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $26,568.43 | 50 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24,135.15 | 31 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21,960.38 | 46 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $4,907.31 | 31 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $424.86 | 17 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $421.26 | 16 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $313.38 | 19 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $196.10 | 16 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $171.92 | 8 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $167.51 | 7 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $154.25 | 15 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $98.53 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $83.84 | 4 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $46.89 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $45.22 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $40.73 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $40.31 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $30.73 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $20.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Azstarys azstarys |
2025 | Azstarys | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 75 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Jornay PM jornay pm |
2025 | Jornay Pm | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LOREEV XR loreev xr |
2025 | Loreev Xr | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Qelbree qelbree |
2025 | Qelbree | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
109 | 20 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Almatica Pharma LLC Exact reporting entity; no affiliate inference |
2025 | LOREEV XR open payments reported associated product |
CMS Open Payments — General Payments 9621 supporting records · 4446 recipient NPIs · example record 1209929018 |
Loreev Xr · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | Jornay PM open payments reported associated product |
CMS Open Payments — General Payments 46719 supporting records · 16334 recipient NPIs · example record 1224105018 |
Jornay Pm · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Corium, LLC Exact reporting entity; no affiliate inference |
2025 | Azstarys open payments reported associated product |
CMS Open Payments — General Payments 54930 supporting records · 15827 recipient NPIs · example record 1185762907 |
Azstarys · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Supernus Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | Qelbree open payments reported associated product |
CMS Open Payments — General Payments 61278 supporting records · 18421 recipient NPIs · example record 1244861775 |
Qelbree · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 1053 | 135 |
| Trazodone Hcl | Trazodone Hcl | 749 | 103 |
| Clonazepam | Clonazepam | 687 | 92 |
| Fluoxetine Hcl | Fluoxetine Hcl | 669 | 99 |
| Sertraline Hcl | Sertraline Hcl | 546 | 68 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 506 | 74 |
| Aripiprazole | Aripiprazole | 471 | 78 |
| Quetiapine Fumarate | Quetiapine Fumarate | 454 | 51 |
| Lorazepam | Lorazepam | 430 | 68 |
| Gabapentin | Gabapentin | 426 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 401 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 376 | 57 |
| Divalproex Sodium Er | Divalproex Sodium | 362 | 40 |
| Lamotrigine | Lamotrigine | 353 | 57 |
| Olanzapine | Olanzapine | 323 | 56 |
| Risperidone | Risperidone | 297 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 293 | 43 |
| Bupropion Xl | Bupropion Hcl | 289 | 57 |
| Buspirone Hcl | Buspirone Hcl | 236 | 38 |
| Topiramate | Topiramate | 189 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 177 | 25 |
| Mirtazapine | Mirtazapine | 175 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 170 | 29 |
| Diazepam | Diazepam | 150 | 24 |
| Benztropine Mesylate | Benztropine Mesylate | 149 | 18 |
| Oxcarbazepine | Oxcarbazepine | 147 | 17 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 142 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 29 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 134 | 17 |
| Divalproex Sodium | Divalproex Sodium | 127 | 19 |
| Ziprasidone Hcl | Ziprasidone Hcl | 124 | 13 |
| Doxepin Hcl | Doxepin Hcl | 121 | 13 |
| Propranolol Hcl | Propranolol Hcl | 116 | 24 |
| Bupropion Hcl Sr | Bupropion Hcl | 113 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 112 | 19 |
| Clonidine Hcl | Clonidine Hcl | 109 | 20 |
| Vraylar | Cariprazine Hcl | 109 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 15 |
| Atomoxetine Hcl | Atomoxetine Hcl | 92 | 16 |
| Lithium Carbonate Er | Lithium Carbonate | 88 | 12 |
| Methylphenidate Hcl | Methylphenidate Hcl | 87 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 84 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 82 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 82 | 13 |
| Temazepam | Temazepam | 81 | 14 |
| Metformin Hcl Er | Metformin Hcl | 80 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 13 |
| Clozapine | Clozapine | 77 | suppressed |
| Ingrezza | Valbenazine Tosylate | 75 | suppressed |
| Haloperidol | Haloperidol | 71 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 66 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 66 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 62 | suppressed |
| Caplyta | Lumateperone Tosylate | 57 | suppressed |
| Paliperidone Er | Paliperidone | 57 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 56 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 55 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | suppressed |
| Memantine Hcl | Memantine Hcl | 49 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 47 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 47 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 46 | suppressed |
| Carbamazepine | Carbamazepine | 45 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 43 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 38 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 37 | suppressed |
| Estradiol | Estradiol | 36 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 31 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 31 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 30 | suppressed |
| Metformin Hcl | Metformin Hcl | 30 | suppressed |
| Amantadine | Amantadine Hcl | 29 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Carbamazepine Er | Carbamazepine | 28 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 27 | suppressed |
| Perphenazine | Perphenazine | 27 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 26 | suppressed |
| Zonisamide | Zonisamide | 26 | suppressed |
| Valtoco | Diazepam | 25 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 24 | suppressed |
| Loxapine | Loxapine Succinate | 23 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Alprazolam Er | Alprazolam | 20 | suppressed |
| Jornay Pm | Methylphenidate Hcl | 20 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 20 | suppressed |
| Loreev Xr | Lorazepam | 19 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 17 | suppressed |
| Lisinopril | Lisinopril | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 16 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 16 | suppressed |
| Nefazodone Hcl | Nefazodone Hcl | 16 | suppressed |
| Adderall | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 15 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Olanzapine-Fluoxetine Hcl | Olanzapine/Fluoxetine Hcl | 14 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 13 | suppressed |
| Azstarys | Serdexmethylphen/Dexmethylphen | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 12 | suppressed |
| Austedo Xr | Deutetrabenazine | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Fetzima | Levomilnacipran Hcl | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Qelbree | Viloxazine Hcl | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79,465.15 · 264 records | Supernus Pharmaceuticals, Inc. | ABILIFY ASIMTUFII, APLENZIN, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, Dyanavel XR, FANAPT, HETLIOZ, INGREZZA, Jornay PM, LOREEV XR, LYBALVI, NUPLAZID, Qelbree, REXULTI, SPRAVATO, Sunosi, TRINTELLIX, VRAYLAR | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error